Skip to main content

Table 1 Overview of patient cohort studies investigating viral and disease factors linked with bnAb development

From: Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

Reference Number of subjectsa Investigated viral and disease factors Association with breadth Additional information on investigated parameter
Doria-Rose et al. [11] 103 Viral load Positive Contemporaneous
Infection duration None  
Transmission mode None  
CD4+ T cell levels None Contemporaneous
History of ART use None  
Euler et al. [6] 82 Viral load Positive Set point
CD4+ T cell levels Negative Set point
Disease progression None  
Gray et al. [33] 40 Viral load Positive Set point
CD4+ T cell levels Negative 6 months post-infection
CD4+ T cell decline Positive Difference between levels pre-infection and at 6 months
Landais et al. [14] 439 Viral load Positive Set point
Infecting subtype Positive Subtype C infection
Infection duration Positive  
Transmission mode None  
CD4+ T cell levels Negative All tested time points beyond 6 months post-infection
Mikkell et al. [32] 38 Viral load Positive Contemporaneous
Piantadosi et al. [48] 70 Viral load Positive Set point
Viral diversity Positive Env
CD4+ T cell levels None Contemporaneous
Disease progression None  
Rusert et al. [12] 4484 Viral load Positive Contemporaneous
Viral diversity Positive Pol
Infecting subtype None  
Infection duration Positive  
Transmission mode Weakly positive Modestly higher bnAb activity in IDUs
CD4+ T cell levels Weakly positive Contemporaneous; modest association with cross-neutralization activity
Sather et al. [49] 39 Viral load Positive Average of all tested time points
Infection duration Positive  
CD4+ T cell levels None Average of all tested time points
van Gils et al. [50] 35 Viral load Positive Set point
CD4+ T cell levels Negative Set point
  1. aIndicates total number of subjects included. Specific analyses may have been carried out on subsets of these numbers
\